Today we announced the initiation of a Phase 1 clinical study evaluating NBIP-‘1968, our internally discovered investigational therapy for obesity.

NBIP-‘1968 is a long-acting triple agonist designed to target the GLP-1, GIP, and glucagon receptors - key pathways involved in appetite regulation, energy balance, and glycemic control.

This milestone marks an important step in advancing our growing metabolic disease portfolio and reflects our commitment to developing differentiated therapies for people living with obesity.

https://neurocrine.gcs-web.com/news-releases/news-release-details/neurocrine-biosciences-announces-initiation-phase-1-clinical-6